Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
After screening titles and abstracts for eligibility, there were N = 313 papers for full-text screening
Egrifta (tesamorelin for injection) US Prescribing Information
and (ii) the indiscriminate substitution of industrialized products already available and approved by ANVISA with compounded products
The company has said, we do not expect the reduction in list price to impact net price. If Novos net revenue per dose remains unchanged, employer health plans would likely see no reduction in their overall spending
US$ 21.25
US$ 24.84
US$ 24.57
US$ 29.27
US$ 24.44
US$ 23.56
